UB Paderborn / Katalog / Suche / in CDI

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

The Lancet (British edition), 2023-01, Vol.401 (10371), p.105-117

2023

Volltextzugriff (PDF)

The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol

BMC cancer, 2019-12, Vol.19 (1), p.1243-11, Article 1243

2019

Volltextzugriff (PDF)

Acceptability, feasibility and preliminary effects of an online group psychotherapy intervention for adolescents and young adults with cancer

Psycho-oncology (Chichester, England), 2024-03, Vol.33 (3), p.e6335-n/a

2024

Volltextzugriff (PDF)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Therapeutic Advances in Medical Oncology, 2022-01, Vol.14, p.17588359211066677

2022

Volltextzugriff (PDF)

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer

Cancers, 2024-01, Vol.16 (3), p.518

2024

Volltextzugriff (PDF)

Surgical excision versus observation as initial management of desmoid tumors: A population based study

European journal of surgical oncology, 2019-04, Vol.45 (4), p.699-703

2019

Volltextzugriff (PDF)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

Current oncology (Toronto), 2023-08, Vol.30 (9), p.8019-8038

2023

Volltextzugriff (PDF)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231175440-17588359231175440

2023

Volltextzugriff (PDF)

HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

Current oncology (Toronto), 2023-06, Vol.30 (6), p.5425-5447

2023

Volltextzugriff (PDF)

Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

Current oncology (Toronto), 2023-08, Vol.30 (8), p.7672-7691

2023

Volltextzugriff (PDF)

Gastrointestinal Stromal Tumor Metastasis to the Orbit

Ophthalmic plastic and reconstructive surgery, 2018-07, Vol.34 (4), p.e131-e133

2018

Volltextzugriff (PDF)

Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta

Canadian Medical Association journal (CMAJ), 2023-06, Vol.195 (23), p.E804-E812

2023

Volltextzugriff (PDF)

Data Resource Profile: The Alberta Adolescent and Young Adult Cancer Survivor Study

International journal of epidemiology, 2022-06, Vol.51 (3), p.e55-e64

2022

Volltextzugriff (PDF)

Symptom severity and trajectories among adolescent and young adult patients with cancer

JNCI cancer spectrum, 2023-10, Vol.7 (6)

2023

Volltextzugriff (PDF)

The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors

Current oncology (Toronto), 2022-04, Vol.29 (5), p.2973-2994

2022

Volltextzugriff (PDF)

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241266179

2024

Volltextzugriff (PDF)

High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma

Leukemia & lymphoma, 2013-12, Vol.54 (12), p.2620-2626

2013

Volltextzugriff (PDF)

Ten ways to get a grip on designing and implementing a competency-based medical education training program

Canadian medical education journal, 2021-04, Vol.12 (2), p.e81-e87

2021

Volltextzugriff (PDF)

Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18798-e18798

2023

Volltextzugriff (PDF)

Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13598-e13598

2023

Volltextzugriff (PDF)

Abstract PO2-17-01: Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-17-01-PO2-17-01

2024

Volltextzugriff (PDF)

Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistance—A compLEEment-1 Canadian correlative sub-study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3170-TPS3170

2019

Volltextzugriff (PDF)

Craniospinal Irradiation for Leptomeningeal Disease in Recurrent Breast Cancer

Applied radiation oncology, 2021-06, p.42-47

2021

Volltextzugriff (PDF)

Treat ER + ight: Treatment of Canadian postmenopausal women with ER + HER2 - advanced breast cancer in the real-world setting with hormone therapy ± targeted therapy

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS614-TPS614

2016

Volltextzugriff (PDF)

Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.GS2-02-GS2-02

2023

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol

Acceptability, feasibility and preliminary effects of an online group psychotherapy intervention for adolescents and young adults with cancer

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer

Surgical excision versus observation as initial management of desmoid tumors: A population based study

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

Gastrointestinal Stromal Tumor Metastasis to the Orbit

Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta

Data Resource Profile: The Alberta Adolescent and Young Adult Cancer Survivor Study

Symptom severity and trajectories among adolescent and young adult patients with cancer

The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada

High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma

Ten ways to get a grip on designing and implementing a competency-based medical education training program

Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status

Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada

Abstract PO2-17-01: Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study

Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistance—A compLEEment-1 Canadian correlative sub-study

Craniospinal Irradiation for Leptomeningeal Disease in Recurrent Breast Cancer

Treat ER + ight: Treatment of Canadian postmenopausal women with ER + HER2 - advanced breast cancer in the real-world setting with hormone therapy ± targeted therapy

Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

Suchergebnisse filtern